Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker UTZ
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 9, 2026 | SCHEDULE 13G | UTZ Utz Brands Inc | Paul J. Glazer | 4.45M | 5.0% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | UTZ Utz Brands Inc | Glazer Capital, LLC | 4.45M | 5.0% | SCHEDULE 13G ↗ |
| Jul 22, 2026 | SCHEDULE 13D/A (amended) | UTZ Utz Brands Inc | Timothy Brown | 67,573 | 0.1% | SCHEDULE 13D/A ↗ |
| Jul 22, 2026 | SCHEDULE 13D/A (amended) | UTZ Utz Brands Inc | Dylan Lissette | 1.39M | 1.6% | SCHEDULE 13D/A ↗ |
| Jul 22, 2026 | SCHEDULE 13D/A (amended) | UTZ Utz Brands Inc | Rice Family Foundation | 900,000 | 1.0% | SCHEDULE 13D/A ↗ |
| Jul 22, 2026 | SCHEDULE 13D/A (amended) | UTZ Utz Brands Inc | Series R of UM Partners LLC | 8.93M | 9.2% | SCHEDULE 13D/A ↗ |
| Jul 22, 2026 | SCHEDULE 13D/A (amended) | UTZ Utz Brands Inc | Series U of UM Partners, LLC | 50.62M | 37.3% | SCHEDULE 13D/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Ameriprise Financial, Inc. | 1.91M | 2.2% | SCHEDULE 13G/A ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | JPMorgan Chase & Co | 4.10M | 4.6% | SCHEDULE 13G/A ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Ameriprise Financial, Inc. | 5.33M | 6.1% | SCHEDULE 13G/A ↗ |
| Jan 23, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | JPMorgan Chase & Co. | 5.27M | 6.0% | SCHEDULE 13G/A ↗ |
| Jan 20, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Israel A. Englander | 2.54M | 2.9% | SCHEDULE 13G/A ↗ |
| Jan 20, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Millennium Group Management LLC | 2.54M | 2.9% | SCHEDULE 13G/A ↗ |
| Jan 20, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Millennium Management LLC | 2.54M | 2.9% | SCHEDULE 13G/A ↗ |
| Jan 20, 2026 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Integrated Core Strategies (US) LLC | 2.42M | 2.8% | SCHEDULE 13G/A ↗ |
| Oct 24, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | JPMorgan Chase & Co. | 7.30M | 8.4% | SCHEDULE 13G/A ↗ |
| Oct 10, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Roger K. Deromedi | 4.77M | 5.5% | SCHEDULE 13G/A ↗ |
| Oct 10, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Chinh E. Chu | 524,716 | 0.6% | SCHEDULE 13G/A ↗ |
| Oct 10, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Jason K. Giordano | 3.81M | 4.4% | SCHEDULE 13G/A ↗ |
| May 28, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Israel A. Englander | 4.52M | 5.3% | SCHEDULE 13G ↗ |
| May 28, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Millennium Group Management LLC | 4.52M | 5.3% | SCHEDULE 13G ↗ |
| May 28, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Millennium Management LLC | 4.52M | 5.3% | SCHEDULE 13G ↗ |
| May 28, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Integrated Core Strategies (US) LLC | 4.44M | 5.2% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Threadneedle Investment Services Limited | 5.31M | 6.2% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Threadneedle Asset Management Limited | 5.31M | 6.2% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | TC Financing Ltd | 5.31M | 6.2% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Threadneedle Asset Management Holdings Limited | 5.31M | 6.2% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | TAM UK Holdings Limited | 5.31M | 6.2% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Threadneedle Holdings Limited | 5.31M | 6.2% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | TAM UK International Holdings Limited | 5.31M | 6.2% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Ameriprise Financial, Inc. | 6.20M | 7.2% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | T. Rowe Price Investment Management, Inc. | 1.49M | 1.7% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Champlain Investment Partners, LLC | 4.02M | 4.7% | SCHEDULE 13G ↗ |
| Apr 24, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | BlackRock, Inc. | 5.00M | 5.8% | SCHEDULE 13G/A ↗ |
| Apr 7, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Israel A. Englander | 1.01M | 1.2% | SCHEDULE 13G/A ↗ |
| Apr 7, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Millennium Group Management LLC | 1.01M | 1.2% | SCHEDULE 13G/A ↗ |
| Apr 7, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Millennium Management LLC | 1.01M | 1.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Ameriprise Financial, Inc. | 4.61M | 5.6% | SCHEDULE 13G ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Chinh E. Chu | 3.38M | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Jason K. Giordano | 5.38M | 6.2% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Israel A. Englander | 4.15M | 5.0% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Millennium Group Management LLC | 4.15M | 5.0% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Millennium Management LLC | 4.15M | 5.0% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | JPMorgan Chase & Co. | 7.81M | 9.4% | SCHEDULE 13G/A ↗ |
| Feb 4, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Neuberger Berman Investment Advisers LLC | 130,377 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 4, 2025 | SCHEDULE 13G/A (amended) | UTZ Utz Brands Inc | Neuberger Berman Group LLC | 157,983 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 4, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Neuberger Berman Investment Advisers LLC | 4.15M | 5.0% | SCHEDULE 13G ↗ |
| Feb 4, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Neuberger Berman Group LLC | 4.18M | 5.1% | SCHEDULE 13G ↗ |
| Jan 23, 2025 | SCHEDULE 13G | UTZ Utz Brands Inc | Israel A. Englander | 3.32M | 4.0% | SCHEDULE 13G ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:27 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances